Skip to main content
OpenTrials
Completed

NCT Number: NCT06258083

Systemic Right Ventricle Long-term Outcome

Patients with the transposition of great arteries (TGA) who undergo atrial switch operation and congenitally corrected TGA (ccTGA) patients have the right ventricle as their systemic ventricle. Function of the systemic right ventricle (SRV) could deteriorate which is associated with impaired prognosis. It is of paramount importance to understand the course and fate of these patients during a long-term follow-up to identify the determinants of adverse outcomes.

Completed

Looking for future studies?

Notify Me

Key information

About this study

In the year 2000, the prevalence of congenital heart diseases (CHD) patients with transposition of great arteries (TGA) was 0.027% in living children and 0.004% in living adults (1). Considering a complete transition to arterial switch operation in the 1990s, it is expected that the number of patients with systemic right ventricle (SRV) decrease over time (2). However, considering the existing number of patients with the TGA who have not undergone arterial switch surgery, SRV remains a challenging issue in the practice of adult congenital heart disease (ACHD) specialists.

TGA is characterized by AV concordance and ventriculo-arterial discordance and is called simple without the presence of associated congenital anomalies. However, complex TGA is when other anomalies are present including VSD (∼45%), LVOTO (∼25%), and CoA (∼5%). TGA's pathogenesis is controversial and there is rare familial occurrence. Male are two times more affected than females. The prognosis of TGA patients without surgery is poor and only exceptional cases survive to adulthood (3).

Heart failure and sudden cardiac death (SCD) are the predominant causes of mortality in TGA patients (4). Patients who undergo atrial switch operation and congenitally corrected TGA (ccTGA) patients are at risk of developing SRV failure in the future (3). The RV is a thin-walled triangular structure acting as a low pressure pump in the normal heart. Because of having only 2 layers, the RV cannot cause the torsion caused by the LV. Due to this geometry and anatomy, the right ventricular function is highly dependent on the loading conditions. The increased afterload that the RV faces in the systemic position causes compensatory RV dilation to maintain the stroke volume. Subsequently, there is increased myocardial wall stress and oxygen demand. The development of heart failure in the SRV is multifactorial. Other potential factors contributing to the SRV failure are impaired coronary reserve or ischemia, myocardial fibrosis, chronotropic incompetence, volume overload from tricuspid regurgitation and arrhythmias (4). Another contributing factor is the reduced baffle compliance in patients with atrial switch. This impairs the preload and stroke volume, especially when there is increased demand. The non-contractile atrial baffles cause impaired atrioventricular transport during tachycardia, therefore causing an inadequate RV filling (4).

Unfortunately, at the moment, the hypothesis that angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), aldosterone antagonists, and beta-blockers can improve the outcome of such patients alone or in combination is not supported by data and evidence. There is no solid recommendation in the 2020 guidelines for the management of ACHD (3).

Previous studies evaluating the fate and outcome of patients with an SRV are either mostly single-centered with a small number of patients or have a short follow-up period (5,6). In a study done by Richard Dobson and colleagues on a national cohort in Scotland, the investigators concluded that patients with an SRV who survive to adulthood have low mortality and good functional status up to the age of 40 (7).

It is of paramount importance to understand the course and fate of these patients during a long-term follow-up to identify the determinants of adverse outcomes. This will enable the investigators to investigate mechanistic pathways of such outcomes. By understanding the risk factors and pathophysiological basis, the investigators can also investigate new diagnostic methods and therapeutic options to improve the quality of life and reduce the mortality of patients with an SRV.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 12 years old and older
  • Surgically corrected transposition of the great arteries (TGA) patients with a systemic right ventricle (SRV) (Mustard, Senning)
  • Congenitally corrected TGA patients with a systemic right ventricle

Exclusion criteria

  • None.

Treatment and study plan

Primary outcomes

  1. All-cause mortality

    Time frame: Through study completion, an average of 18 years

    Death

  2. Incident heart failure

    Time frame: Through study completion, an average of 18 years

    Initiation or increase in dosage (if previously prescribed for another cause, i.e. hypertension) of loop diuretic, ACE-inhibitor/ARB therapy, or evidence-based beta blocker therapy because of new heart failure signs and symptoms (shortness of breath, fatigue, reduced exercise tolerance) AND AT LEAST 1 OF THE FOLLOWING: • BNP ≥400 pg/mL OR the following NT-proBNP levels according to age: < 50 years, ≥450 ng/L; 50-75 years, ≥900 ng/L; >75 years, ≥1800 ng/L OR systolic dysfunction (Systemic ventricle EF <50%) OR • BNP 100-400 pg/mL (or NT-proBNP levels below the thresholds according to age given above) AND structural or functional heart disease

  3. Number of patients with heart failure hospitalization

    Time frame: Through study completion, an average of 18 years

    Rehospitalization, emergency ward visit, 24h observation stay AND Treatment with or increase in dosage if previously prescribed for another cause (i.e.hypertension) of loop diuretics or treatment with IV vasoactive agents.

  4. Number of patients with arrhythmias

    Time frame: Through study completion, an average of 18 years

    Events that cause emergency ward visit or hospitalization.

  5. Number of patients with thromboembolic events

    Time frame: Through study completion, an average of 18 years

    Cerebrovascular events including any of (Hemorrhagic or ischemic): 1, TIA (symptoms less than 24 hours) 2, CVA (symptoms more than 24 hours) and also pulmonary embolism.

  6. Infective endocarditis

    Time frame: Through study completion, an average of 18 years

    Definitie Infective Endocarditis

  7. Number of patients with tricuspid valve surgery

    Time frame: Through study completion, an average of 18 years

    Tricuspid valve surgery

  8. Number of patients with ventricular Assist Device implantation

    Time frame: Through study completion, an average of 18 years

    Implantation of ventricular assist device

  9. Number of patients with heart transplantation

    Time frame: Through study completion, an average of 18 years

    Heart transplantation

  10. Number of patients with aortic aneurysm or dissection

    Time frame: Through study completion, an average of 18 years

    Aortic root more than 40 mm or aneurysm in other parts of aorta. Aortic dissection.

  11. Number of patients with pulmonary artery hypertension

    Time frame: Through study completion, an average of 18 years

    Mean PAP of more than 25mmHg or systolic PAP of more than 40 mmHg.

  12. Number of patients with baffle interventions

    Time frame: Through study completion, an average of 18 years

    Surgical or angiographic reintervention of baffles in patients with surgically corrected transposition of the great arteries (due to stenosis or leakage).

  13. Number of patients with coronary artery interventions

    Time frame: Through study completion, an average of 18 years

    Due to ischemia. Angiographic or surgical intervention.

  14. Number of patients with device implantation

    Time frame: Through study completion, an average of 18 years

    Including pacmakers, ICDs and CRTs.

Secondary outcomes

  1. Number of patients with decreased exercise capacity

    Time frame: At two time points. 1: Baseline 2. Through study completion, an average of 18 years

    Evaluated by cardiopulmonary exercise test results.

  2. Number of patients with right ventricular systolic dysfunction

    Time frame: At two time points. 1: Baseline 2. Through study completion, an average of 18 years

    Measured by echocardiography qualitatively

  3. Number of patients with left ventricular systolic dysfunction

    Time frame: At two time points. 1: Baseline 2. Through study completion, an average of 18 years

    Measured by echocardiography qualitatively

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Collaborators

  • Hartekind
  • Hartstichting

Registry information

Official study title

Systemic Right Ventricle Long-term Outcome: a Multicentre Study

Acronym: SINCERE

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Feb 14, 2024
Registry last updated
Feb 14, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.